Knight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan bought 17,600 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was purchased at an average price of C$5.48 per share, with a total value of C$96,488.48.
Knight Therapeutics Trading Up 0.9 %
TSE GUD opened at C$5.60 on Thursday. Knight Therapeutics Inc. has a 12 month low of C$5.09 and a 12 month high of C$6.23. The company has a debt-to-equity ratio of 7.52, a current ratio of 3.36 and a quick ratio of 1.79. The company has a market capitalization of C$566.44 million, a price-to-earnings ratio of -18.70, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The company's fifty day moving average price is C$5.53 and its two-hundred day moving average price is C$5.56.
Wall Street Analyst Weigh In
Separately, Raymond James upgraded shares of Knight Therapeutics to a "moderate buy" rating in a research note on Friday, November 15th.
Get Our Latest Analysis on Knight Therapeutics
About Knight Therapeutics
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
